Rua Bioscience（RUA）株式概要ルア・バイオサイエンス・リミテッドは、ニュージーランドおよび海外で医薬品の研究、開発、製造を行っている。 詳細RUA ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ キャッシュランウェイが1年未満である 過去5年間で収益は年間5.2%減少しました。 意味のある時価総額がありません ( NZ$9M )+1 さらなるリスクすべてのリスクチェックを見るRUA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNZ$Current PriceNZ$0.02827.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m12m2016201920222025202620282031Revenue NZ$12.2mEarnings NZ$1.8mAdvancedSet Fair ValueView all narrativesRua Bioscience Limited 競合他社BLIS TechnologiesSymbol: NZSE:BLTMarket cap: NZ$19.2mAFT PharmaceuticalsSymbol: NZSE:AFTMarket cap: NZ$406.9mHerbal DispatchSymbol: CNSX:HERBMarket cap: CA$8.0mODI PharmaSymbol: NGM:ODIMarket cap: SEK 71.5m価格と性能株価の高値、安値、推移の概要Rua Bioscience過去の株価現在の株価NZ$0.02852週高値NZ$0.05952週安値NZ$0.024ベータ0.491ヶ月の変化-9.68%3ヶ月変化-17.65%1年変化-6.67%3年間の変化-82.50%5年間の変化-93.25%IPOからの変化-95.88%最新ニュースNew Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.4m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 5.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (NZ$11.5m market cap, or US$6.90m). Minor Risk Revenue is less than US$5m (NZ$2.4m revenue, or US$1.4m).Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Tony Barclay was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Jan 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (NZ$9.47m market cap, or US$5.46m). Minor Risk Revenue is less than US$5m (NZ$1.8m revenue, or US$1.1m).Reported Earnings • Oct 04Full year 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.018 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.83m (up 477% from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Sep 12Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million.Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,666,666 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,733,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,666,667 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 666,667 Price\Range: NZD 0.03 Transaction Features: Subsequent Direct ListingReported Earnings • Sep 02Full year 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.02 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.90m (up NZ$1.58m from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesNew Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.4m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 5.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (NZ$11.5m market cap, or US$6.90m). Minor Risk Revenue is less than US$5m (NZ$2.4m revenue, or US$1.4m).Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Tony Barclay was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Jan 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (NZ$9.47m market cap, or US$5.46m). Minor Risk Revenue is less than US$5m (NZ$1.8m revenue, or US$1.1m).Reported Earnings • Oct 04Full year 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.018 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.83m (up 477% from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Sep 12Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million.Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,666,666 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,733,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,666,667 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 666,667 Price\Range: NZD 0.03 Transaction Features: Subsequent Direct ListingReported Earnings • Sep 02Full year 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.02 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.90m (up NZ$1.58m from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.お知らせ • Aug 15Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025.New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$629k). Market cap is less than US$10m (NZ$6.49m market cap, or US$3.83m).New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$3.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$595k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.55m).New Risk • Feb 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 38% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$316k revenue, or US$179k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.60m).お知らせ • Jan 21Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine AddictionRua Bioscience announced its support for a clinical study that harnesses the potential of psilocybin-containing mushrooms to treat methamphetamine addiction. This pioneering research, rooted in an indigenous community and guided by mtauranga Mori, has reached a significant milestone. Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessions with mushroom extract containing a specific dose of psilocybin at Rangiwaho Marae, near Gisborne. This marks an important step in Phase I of the trial. Learnings from this first phase will guide the next steps, focusing on the intervention's safety, acceptability, feasibility, and alignment with tikanga and mtauranga Mori. Collaborative Effort Rooted in Tikanga Mori: The study, named T Wairua (standing with strength and spiritual connectedness), represents a collaboration among Rangiwaho Marae, Rua Bioscience, and other research and health organizations. The initiative blends local Mori knowledge with cutting-edge scientific research to explore the therapeutic potential of indigenous Psilocybe fungi (taonga). Tu Wairua is undertaking cultivation trials of taonga varieties with the support from Rua Bioscience and Manaaki Whenua Landcare Research and the Institute of Environmental Science and Research (ESR) is providing analytical support. The psilocybin used in this trial was supplied by Canadian company Optimi Health. Marae-based kaitieki (guides) have been trained in collaboration with kaupapa Mori and psychedelic therapy trainers to provide culturally informed support for participants throughout the trial. Phase I of the study received full approval earlier 2025 from both the Health & Disability Ethics Committees (HDEC) and the Standing Committee on Therapeutic Trials (SCOTT). The research team is currently fundraising for Phase II of the clinical trial, which will expand upon these early findings.お知らせ • Dec 19Rua Bioscience Announces Launch of New Products in the UKRua Bioscience announced the launch of three medicinal cannabis products in the United Kingdom. This marks a significant milestone in Rua's international growth strategy, with the UK positioned as a key market alongside Germany, Australia, and New Zealand. These new products will be distributed exclusively by Target Healthcare, a leading distributor of unlicenced medicines in the UK. Unlocking the Potential of a Growing Market The UK medicinal cannabis market is estimated to be one of the fastest growing in Europe, driven by an increasing number of patients seeking alternative medicines for the treatment of chronic pain, anxiety, and other conditions. The market is approximately $60m and growing at over 100% per annum in the last two years. With a population of 68 million, Rua expects this market to grow significantly in the next two years. Rua's entry into this market is the next stage in the establishment of a consistent supply line and respected presence.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$188k). Market cap is less than US$10m (NZ$5.08m market cap, or US$3.02m). Minor Risk Shareholders have been diluted in the past year (3.5% increase in shares outstanding).お知らせ • Oct 21Rua Bioscience Limited Provides Sales Results for the Year 2025Rua Bioscience Limited provided sales results for the year 2025. The company expects to see all markets continue to grow over the medium term as medicinal cannabis gains acceptance and is understood as a legitimate, safe and efficacious treatment option in key markets. Importantly this means sales revenue will continue to grow as the company now firmly established in three key markets with strong revenue growth. In addition, the company is expected to launch Rua product in a fourth key market, United Kingdom, in the next two months. It is for these reasons that The company expects 2025 revenue to show significant growth.New Risk • Oct 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$192k). Market cap is less than US$10m (NZ$7.86m market cap, or US$4.77m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (3.5% increase in shares outstanding).Reported Earnings • Oct 05Full year 2024 earnings released: NZ$0.087 loss per share (vs NZ$0.039 loss in FY 2023)Full year 2024 results: NZ$0.087 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 30Full year 2024 earnings released: NZ$0.09 loss per share (vs NZ$0.039 loss in FY 2023)Full year 2024 results: NZ$0.09 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 19Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024.New Risk • Feb 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.0% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$406k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.61m).New Risk • Jan 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NZ$15.8m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$409k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.67m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).New Risk • Oct 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$389k). Market cap is less than US$10m (NZ$16.6m market cap, or US$9.67m). Minor Risk Shareholders have been diluted in the past year (5.5% increase in shares outstanding).お知らせ • Sep 05Rua Bioscience Launches First Product in AustraliaRua Bioscience announced its official entry into the dynamic Australian medicinal cannabis market. Teaming up with Anspec, a leading pharmaceutical distribution company, Rua Bioscience product is now available to Australian patients through prescribers. In 2022, the Australian cannabis market was valued at AUD 240 million per year.Reported Earnings • Aug 30Full year 2023 earnings released: NZ$0.04 loss per share (vs NZ$0.06 loss in FY 2022)Full year 2023 results: NZ$0.04 loss per share (improved from NZ$0.06 loss in FY 2022). Net loss: NZ$5.96m (loss narrowed 31% from FY 2022).お知らせ • Aug 18Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023, at 10:00 NZST - New Zealand Standard.New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of New Zealander stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.9m free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (NZ$526k revenue, or US$327k). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (NZ$24.8m market cap, or US$15.5m).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 21Rua Bioscience Limited Announces Executive ChangesRua Bioscience Limited announces that Andi Grant is to step down from the role of Chief Commercial Officer. The role will be filled by current Chief Operating Officer, Paul Naske. Andi joined Rua in June 2021 and has substantially progressed Rua's global and New Zealand business goals. Paul Naske has been overseeing Rua's topline business operations since the beginning of 2019 and has been critical in the design and efficient execution of Rua's global strategy.Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Trevor Burt was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 26Rua Bioscience Limited to Report Fiscal Year 2022 Results on Aug 29, 2022Rua Bioscience Limited announced that they will report fiscal year 2022 results on Aug 29, 2022お知らせ • Aug 23Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022, at 10:00 NZST - New Zealand Standard. Location: Waikanae Surf Club, Grey St Gisborne New Zealand分析記事 • May 13Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Apr 19Rua Bioscience Limited Launches Its First Medicine in New ZealandRua Bioscience has launched its first medicine, marking a significant milestone for New Zealand patients, prescribers and the medicinal cannabis industry. Available on prescription in New Zealand, GPs and specialists who are registered medical practitioners will now be able to include Rua medicine in patient treatment plans. Manufactured in the company's purpose-built facility in Gisborne, and distributed nationally via CDC Pharmaceuticals, sales from the product will be the first revenue for the business, which listed on the NZX in 2020.Board Change • Dec 31High number of new directorsNon-Executive Director Brett Gamble was the last director to join the board, commencing their role in 2019.お知らせ • Dec 17Rua Bioscience Given the Green Light to Distribute First Product to New Zealand PatientsRua Bioscience has received verification that its first medicinal cannabis product meets the NZ Medicinal Cannabis Agency's (Medsafe's) quality standards, enabling the company to distribute its first medicine in New Zealand. The approval of the product means that New Zealand patients and prescribers can include the Rua product in their treatment plan. The company intends to distribute product by the end of first quarter, early second quarter 2022. It will be made available as a prescription-only medicine through GPs and specialists. The company be will manufacturing the medicine in its purpose-built facility in Gisborne, having gained Good Manufacturing Practice (GMP) certification for the product earlier 2021.分析記事 • Dec 17Companies Like Rua Bioscience (NZSE:RUA) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Dec 02Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million on November 30, 2021. The consideration at Enterprise value of NZD 8.5 million is net of Zalm Cash. The consideration will be satisfied through issue of 24,420,000 new Rua shares at approximately NZD 0.41 (based on 60-day VWAP) in three tranches, first tranche of shares to the value of NZD 3.3 million in 8,140,000 shares will be issued on completion of the transaction. The remaining consideration will be paid in equal instalments, conditional on Zalm achieving critical production, pricing and regulatory milestones by December 30, 2022 and March 31, 2024 respectively. If neither of the two milestones is achieved, approximately NZD 0.5 million of cash will be released to Cann Group and Rua would have paid NZD 3.3 million for Zalm ( NZD 2.3 million net of cash). Peter Crock, Cann’s Chief Executive Officer and Allan McCallum, AO, Cann’s Chairman, will both step down as directors of Zalm as part of the transaction, while Peter Crock and Shane Duncan (Cann’s Chief Operating Officer), will join the Transition Advisory Board to help maximise and accelerate the potential of this opportunity. The transaction is subject to approval from Rua’s shareholders, which is expected to occur by January 31, 2022.分析記事 • Jul 02Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Mar 09Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Feb 26New 90-day low: NZ$0.48The company is down 15% from its price of NZ$0.57 on 27 November 2020. The New Zealander market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: NZ$0.50The company is down 24% from its price of NZ$0.66 on 30 October 2020. The New Zealander market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.株主還元RUANZ PharmaceuticalsNZ 市場7D-3.4%-0.3%-1.1%1Y-6.7%-12.1%1.2%株主還元を見る業界別リターン: RUA過去 1 年間で-12.1 % の収益を上げたNZ Pharmaceuticals業界を上回りました。リターン対市場: RUAは、過去 1 年間で1.2 % のリターンを上げたNZ市場を下回りました。価格変動Is RUA's price volatile compared to industry and market?RUA volatilityRUA Average Weekly Movement4.4%Pharmaceuticals Industry Average Movement10.3%Market Average Movement4.1%10% most volatile stocks in NZ Market7.9%10% least volatile stocks in NZ Market2.9%安定した株価: RUA 、 NZ市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: RUAの 週次ボラティリティ は、過去 1 年間で10%から4%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2016n/aPaul Naskewww.ruabio.comルア・バイオサイエンス社は、ニュージーランドおよび海外で医薬品の研究・開発・製造を行っている。同社はカンナビノイド由来の医薬品を提供している。また、種子生産や遺伝子探索関連事業も行っている。また、植物育種事業や植物研究活動も行っている。Rua Bioscience Limitedの前身はHikurangi Cannabis Company Limitedで、2019年10月にRua Bioscience Limitedに社名変更した。同社は2016年に設立され、ニュージーランドのギズボーンを拠点としている。もっと見るRua Bioscience Limited 基礎のまとめRua Bioscience の収益と売上を時価総額と比較するとどうか。RUA 基礎統計学時価総額NZ$9.47m収益（TTM）-NZ$3.45m売上高(TTM)NZ$2.39m4.0xP/Sレシオ-2.7xPER（株価収益率RUA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RUA 損益計算書（TTM）収益NZ$2.39m売上原価NZ$1.39m売上総利益NZ$1.00mその他の費用NZ$4.45m収益-NZ$3.45m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.01グロス・マージン41.88%純利益率-144.06%有利子負債／自己資本比率30.3%RUA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:32終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rua Bioscience Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.4m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 5.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (NZ$11.5m market cap, or US$6.90m). Minor Risk Revenue is less than US$5m (NZ$2.4m revenue, or US$1.4m).
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Tony Barclay was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Jan 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (NZ$9.47m market cap, or US$5.46m). Minor Risk Revenue is less than US$5m (NZ$1.8m revenue, or US$1.1m).
Reported Earnings • Oct 04Full year 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.018 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.83m (up 477% from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Sep 12Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million.Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,666,666 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,733,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,666,667 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 666,667 Price\Range: NZD 0.03 Transaction Features: Subsequent Direct Listing
Reported Earnings • Sep 02Full year 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.02 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.90m (up NZ$1.58m from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
New Risk • Mar 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$2.4m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 5.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (NZ$11.5m market cap, or US$6.90m). Minor Risk Revenue is less than US$5m (NZ$2.4m revenue, or US$1.4m).
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Tony Barclay was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Jan 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (NZ$9.47m market cap, or US$5.46m). Minor Risk Revenue is less than US$5m (NZ$1.8m revenue, or US$1.1m).
Reported Earnings • Oct 04Full year 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.018 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.83m (up 477% from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Sep 12Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million.Rua Bioscience Limited has completed a Follow-on Equity Offering in the amount of NZD 0.504 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,666,666 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,733,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,333,333 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,666,667 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 400,000 Price\Range: NZD 0.03 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 666,667 Price\Range: NZD 0.03 Transaction Features: Subsequent Direct Listing
Reported Earnings • Sep 02Full year 2025 earnings released: NZ$0.02 loss per share (vs NZ$0.087 loss in FY 2024)Full year 2025 results: NZ$0.02 loss per share (improved from NZ$0.087 loss in FY 2024). Revenue: NZ$1.90m (up NZ$1.58m from FY 2024). Net loss: NZ$3.46m (loss narrowed 75% from FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
お知らせ • Aug 15Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025Rua Bioscience Limited, Annual General Meeting, Oct 28, 2025.
New Risk • May 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$629k). Market cap is less than US$10m (NZ$6.49m market cap, or US$3.83m).
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$3.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.5m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$1.1m revenue, or US$595k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.55m).
New Risk • Feb 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 38% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m (NZ$316k revenue, or US$179k). Market cap is less than US$10m (NZ$6.35m market cap, or US$3.60m).
お知らせ • Jan 21Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine AddictionRua Bioscience announced its support for a clinical study that harnesses the potential of psilocybin-containing mushrooms to treat methamphetamine addiction. This pioneering research, rooted in an indigenous community and guided by mtauranga Mori, has reached a significant milestone. Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessions with mushroom extract containing a specific dose of psilocybin at Rangiwaho Marae, near Gisborne. This marks an important step in Phase I of the trial. Learnings from this first phase will guide the next steps, focusing on the intervention's safety, acceptability, feasibility, and alignment with tikanga and mtauranga Mori. Collaborative Effort Rooted in Tikanga Mori: The study, named T Wairua (standing with strength and spiritual connectedness), represents a collaboration among Rangiwaho Marae, Rua Bioscience, and other research and health organizations. The initiative blends local Mori knowledge with cutting-edge scientific research to explore the therapeutic potential of indigenous Psilocybe fungi (taonga). Tu Wairua is undertaking cultivation trials of taonga varieties with the support from Rua Bioscience and Manaaki Whenua Landcare Research and the Institute of Environmental Science and Research (ESR) is providing analytical support. The psilocybin used in this trial was supplied by Canadian company Optimi Health. Marae-based kaitieki (guides) have been trained in collaboration with kaupapa Mori and psychedelic therapy trainers to provide culturally informed support for participants throughout the trial. Phase I of the study received full approval earlier 2025 from both the Health & Disability Ethics Committees (HDEC) and the Standing Committee on Therapeutic Trials (SCOTT). The research team is currently fundraising for Phase II of the clinical trial, which will expand upon these early findings.
お知らせ • Dec 19Rua Bioscience Announces Launch of New Products in the UKRua Bioscience announced the launch of three medicinal cannabis products in the United Kingdom. This marks a significant milestone in Rua's international growth strategy, with the UK positioned as a key market alongside Germany, Australia, and New Zealand. These new products will be distributed exclusively by Target Healthcare, a leading distributor of unlicenced medicines in the UK. Unlocking the Potential of a Growing Market The UK medicinal cannabis market is estimated to be one of the fastest growing in Europe, driven by an increasing number of patients seeking alternative medicines for the treatment of chronic pain, anxiety, and other conditions. The market is approximately $60m and growing at over 100% per annum in the last two years. With a population of 68 million, Rua expects this market to grow significantly in the next two years. Rua's entry into this market is the next stage in the establishment of a consistent supply line and respected presence.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$188k). Market cap is less than US$10m (NZ$5.08m market cap, or US$3.02m). Minor Risk Shareholders have been diluted in the past year (3.5% increase in shares outstanding).
お知らせ • Oct 21Rua Bioscience Limited Provides Sales Results for the Year 2025Rua Bioscience Limited provided sales results for the year 2025. The company expects to see all markets continue to grow over the medium term as medicinal cannabis gains acceptance and is understood as a legitimate, safe and efficacious treatment option in key markets. Importantly this means sales revenue will continue to grow as the company now firmly established in three key markets with strong revenue growth. In addition, the company is expected to launch Rua product in a fourth key market, United Kingdom, in the next two months. It is for these reasons that The company expects 2025 revenue to show significant growth.
New Risk • Oct 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$3.7m free cash flow). Earnings have declined by 38% per year over the past 5 years. Revenue is less than US$1m (NZ$316k revenue, or US$192k). Market cap is less than US$10m (NZ$7.86m market cap, or US$4.77m). Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Shareholders have been diluted in the past year (3.5% increase in shares outstanding).
Reported Earnings • Oct 05Full year 2024 earnings released: NZ$0.087 loss per share (vs NZ$0.039 loss in FY 2023)Full year 2024 results: NZ$0.087 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 30Full year 2024 earnings released: NZ$0.09 loss per share (vs NZ$0.039 loss in FY 2023)Full year 2024 results: NZ$0.09 loss per share (further deteriorated from NZ$0.039 loss in FY 2023). Net loss: NZ$13.7m (loss widened 130% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 19Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024Rua Bioscience Limited, Annual General Meeting, Oct 15, 2024.
New Risk • Feb 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.0% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$406k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.61m).
New Risk • Jan 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NZ$15.8m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$409k). Market cap is less than US$10m (NZ$15.8m market cap, or US$9.67m). Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).
New Risk • Oct 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of New Zealander stocks, typically moving 7.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.0m free cash flow). Share price has been highly volatile over the past 3 months (7.2% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (NZ$668k revenue, or US$389k). Market cap is less than US$10m (NZ$16.6m market cap, or US$9.67m). Minor Risk Shareholders have been diluted in the past year (5.5% increase in shares outstanding).
お知らせ • Sep 05Rua Bioscience Launches First Product in AustraliaRua Bioscience announced its official entry into the dynamic Australian medicinal cannabis market. Teaming up with Anspec, a leading pharmaceutical distribution company, Rua Bioscience product is now available to Australian patients through prescribers. In 2022, the Australian cannabis market was valued at AUD 240 million per year.
Reported Earnings • Aug 30Full year 2023 earnings released: NZ$0.04 loss per share (vs NZ$0.06 loss in FY 2022)Full year 2023 results: NZ$0.04 loss per share (improved from NZ$0.06 loss in FY 2022). Net loss: NZ$5.96m (loss narrowed 31% from FY 2022).
お知らせ • Aug 18Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023Rua Bioscience Limited, Annual General Meeting, Oct 11, 2023, at 10:00 NZST - New Zealand Standard.
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of New Zealander stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NZ$6.9m free cash flow). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (NZ$526k revenue, or US$327k). Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (NZ$24.8m market cap, or US$15.5m).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Teresa Farac-Ciprian was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 21Rua Bioscience Limited Announces Executive ChangesRua Bioscience Limited announces that Andi Grant is to step down from the role of Chief Commercial Officer. The role will be filled by current Chief Operating Officer, Paul Naske. Andi joined Rua in June 2021 and has substantially progressed Rua's global and New Zealand business goals. Paul Naske has been overseeing Rua's topline business operations since the beginning of 2019 and has been critical in the design and efficient execution of Rua's global strategy.
Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Trevor Burt was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 26Rua Bioscience Limited to Report Fiscal Year 2022 Results on Aug 29, 2022Rua Bioscience Limited announced that they will report fiscal year 2022 results on Aug 29, 2022
お知らせ • Aug 23Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022Rua Bioscience Limited, Annual General Meeting, Oct 12, 2022, at 10:00 NZST - New Zealand Standard. Location: Waikanae Surf Club, Grey St Gisborne New Zealand
分析記事 • May 13Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Apr 19Rua Bioscience Limited Launches Its First Medicine in New ZealandRua Bioscience has launched its first medicine, marking a significant milestone for New Zealand patients, prescribers and the medicinal cannabis industry. Available on prescription in New Zealand, GPs and specialists who are registered medical practitioners will now be able to include Rua medicine in patient treatment plans. Manufactured in the company's purpose-built facility in Gisborne, and distributed nationally via CDC Pharmaceuticals, sales from the product will be the first revenue for the business, which listed on the NZX in 2020.
Board Change • Dec 31High number of new directorsNon-Executive Director Brett Gamble was the last director to join the board, commencing their role in 2019.
お知らせ • Dec 17Rua Bioscience Given the Green Light to Distribute First Product to New Zealand PatientsRua Bioscience has received verification that its first medicinal cannabis product meets the NZ Medicinal Cannabis Agency's (Medsafe's) quality standards, enabling the company to distribute its first medicine in New Zealand. The approval of the product means that New Zealand patients and prescribers can include the Rua product in their treatment plan. The company intends to distribute product by the end of first quarter, early second quarter 2022. It will be made available as a prescription-only medicine through GPs and specialists. The company be will manufacturing the medicine in its purpose-built facility in Gisborne, having gained Good Manufacturing Practice (GMP) certification for the product earlier 2021.
分析記事 • Dec 17Companies Like Rua Bioscience (NZSE:RUA) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Dec 02Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million on November 30, 2021. The consideration at Enterprise value of NZD 8.5 million is net of Zalm Cash. The consideration will be satisfied through issue of 24,420,000 new Rua shares at approximately NZD 0.41 (based on 60-day VWAP) in three tranches, first tranche of shares to the value of NZD 3.3 million in 8,140,000 shares will be issued on completion of the transaction. The remaining consideration will be paid in equal instalments, conditional on Zalm achieving critical production, pricing and regulatory milestones by December 30, 2022 and March 31, 2024 respectively. If neither of the two milestones is achieved, approximately NZD 0.5 million of cash will be released to Cann Group and Rua would have paid NZD 3.3 million for Zalm ( NZD 2.3 million net of cash). Peter Crock, Cann’s Chief Executive Officer and Allan McCallum, AO, Cann’s Chairman, will both step down as directors of Zalm as part of the transaction, while Peter Crock and Shane Duncan (Cann’s Chief Operating Officer), will join the Transition Advisory Board to help maximise and accelerate the potential of this opportunity. The transaction is subject to approval from Rua’s shareholders, which is expected to occur by January 31, 2022.
分析記事 • Jul 02Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Mar 09Here's Why We're Not Too Worried About Rua Bioscience's (NZSE:RUA) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Feb 26New 90-day low: NZ$0.48The company is down 15% from its price of NZ$0.57 on 27 November 2020. The New Zealander market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: NZ$0.50The company is down 24% from its price of NZ$0.66 on 30 October 2020. The New Zealander market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.
